Your browser of choice has not been tested for use with Barchart.com. If you have issues, please download one of the browsers listed here.
Join Barchart Premier for advanced OPTIONS screeners and volatility tools. FREE 30 Day Trial
Stocks | Futures | Watchlist | More
or

Celldex Therapeutics (CLDX)

Celldex Therapeutics (CLDX)
[[ item.lastPrice ]] [[ item.priceChange ]] ([[ item.percentChange ]]) [[ item.tradeTime ]] [NASDAQ]
[[ item.bidPrice ]] x [[ item.bidSize ]] [[ item.askPrice ]] x [[ item.askSize ]]
[[ session ]] by (Cboe BZX)
[[ item.lastPrice ]] [[ item.priceChange ]] ([[ item.percentChange ]]) [[ item.tradeTime ]] [NASDAQ]
[[ item.bidPrice ]] x [[ item.bidSize ]] [[ item.askPrice ]] x [[ item.askSize ]]
[[ session ]] [[ item.lastPriceExt ]] [[ item.priceChangeExt ]] ([[ item.percentChangeExt ]]) [[ item.tradeTimeExt ]]
Profile for [[ item.sessionDateDisplayLong ]]

Company Info

Celldex Therapeutics 53 FRONTAGE ROAD SUITE 220 HAMPTON NJ 08827 USA

www.celldex.com P: 908-200-7500 F: 908-454-1911

Description:

CELLDEX THERAPEUTICS is an integrated biopharmaceutical company that applies its comprehensive Precision Targeted Immunotherapy Platform to generate a pipeline of candidates to treat cancer and other difficult-to-treat diseases. Celldex's immunotherapy platform includes a complementary portfolio of monoclonal antibodies, antibody-targeted vaccines and immunomodulators to create novel disease-specific drug candidates.

Key Statistics

Overview:

Market Capitalization, $K 2,631,167
Enterprise Value, $K 2,596,357
Shares Outstanding, K 65,911
Annual Sales, $ 6,880 K
Annual Net Income, $ -141,430 K
Last Quarter Sales, $ 4,130 K
Last Quarter Net Income, $ -43,310 K
EBIT, $ -142,050 K
EBITDA, $ -145,260 K
60-Month Beta 1.60
% of Insider Shareholders 3.70%
Float, K 63,472
% Float 96.30%
Short Volume Ratio 0.25

Growth:

1-Year Return 18.92%
3-Year Return 47.36%
5-Year Return 1,179.49%
5-Year Revenue Growth -27.88%
5-Year Earnings Growth 61.00%
5-Year Dividend Growth 0.00%

Per-Share Information:

Most Recent Earnings -0.56 on 05/06/24
Latest Earnings Date 05/02/24
Earnings Per Share ttm -2.65
EPS Growth vs. Prev Qtr 1.75%
EPS Growth vs. Prev Year 9.68%
Annual Dividend Yield 0.00%
Dividend Payout Ratio 0.00%
Most Recent Split 1-15 on 02/11/19

CLDX Ratios

Ratio
Price/Earnings ttm 0.00
Price/Earnings forward N/A
Price/Earnings to Growth N/A
Return-on-Equity % -29.55%
Return-on-Assets % -27.66%
Profit Margin % -2,055.67%
Debt/Equity 0.00
Price/Sales 393.19
Price/Cash Flow N/A
Price/Book 2.74
Book Value/Share 9.08
Interest Coverage -2.26
Want to use this as
your default charts setting?
Save this setup as a Chart Templates
Switch the Market flag
for targeted data from your country of choice.
Open the menu and switch the
Market flag for targeted data from your country of choice.
Want Streaming Chart Updates?
Switch your Site Preferences
to use Interactive Charts
Need More Chart Options?
Right-click on the chart to open the Interactive Chart menu.

Free Barchart Webinar